HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 24 September 2012

Recent CUAs

Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers.  36 papers were listed this time. Here's a couple  in our areas of research interest:

Reed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med. 2012 Sep 13. [Epub ahead of print] PubMed PMID: 22975761.

Blohmer JU, Rezai M, Kümmel S, et al. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. J Med Econ. 2012 Sep 11. [Epub ahead of print] PubMed PMID: 22966753.